阿伐曲泊帕治疗中国儿童原发免疫性血小板减少症的长期疗效与安全性:一项真实世界观察性研究
该真实世界观察性研究纳入94例接受阿伐曲泊帕治疗至少4周的原发免疫性血小板减少症(ITP)患儿,中位年龄7.43岁;6岁以下儿童中位有效剂量为10 mg,18岁以下为20 mg。4周和12周总体缓解率分别为72.3%(68/94)和73.4%(58/79),24周和48周持续缓解率分别为62.3%(33/53)和51.6%(16/31);随访期间出血事件、挽救治疗和合并ITP用药减少,血小板增多症(血小板计数≥400×10⁹/L)为最常见不良事件,发生于44例儿童共97次。
要点
- 4周和12周总体缓解率分别为72.3%(68/94)和73.4%(58/79)。
- 24周和48周持续缓解率分别为62.3%(33/53)和51.6%(16/31)。
- 血小板增多症(血小板计数≥400×10⁹/L)为最常见不良事件,44例儿童共97次。
核心结论
- 长期阿伐曲泊帕治疗ITP患儿显示快速且持续的血小板反应和良好的出血控制,无显著或新发不良事件。
研究设计与样本
- 真实世界观察性研究,纳入94例诊断为ITP并接受阿伐曲泊帕治疗至少4周的儿童,中位年龄7.43岁(四分位距4.82,10.80)。
主要发现
- 6岁以下儿童中位有效剂量为10 mg(四分位距10,20),18岁以下儿童为20 mg(四分位距20,40)。
- 4周和12周总体缓解率分别为72.3%(68/94)和73.4%(58/79)。
- 24周和48周持续缓解率分别为62.3%(33/53)和51.6%(16/31)。
- 随访期间出血事件、挽救治疗和合并ITP用药减少。
- 血小板增多症(血小板计数≥400×10⁹/L)为最常见不良事件,发生于44例儿童共97次。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Avatrombopag is a newly approved thrombopoietin receptor agonist for second-line treatment of chronic immune thrombocytopenia (ITP) in adults. Our previous study showed its efficacy and safety in a small sample of paediatric ITP patients. However, large samples and long-term data are still lacking. Children diagnosed with ITP and treated with avatrombopag for at least 4 weeks were enrolled. In 94 ITP patients with a median age of 7.43 (interquartile range (IQR), 4.82, 10.80) years, the median effective dose was 10 (IQR, 10, 20) mg for children under 6 years old and 20 (IQR, 20, 40) mg for children under 18 years old. The overall response was achieved in 72.3% (68/94) and 73.4% (58/79) of patients within 4 weeks and 12 weeks. The sustained response at 24 weeks and 48 weeks were 62.3% (33/53) and 51.6% (16/31) respectively. The occurrence of bleeding events, rescue therapy and concomitant ITP medication decreased during the follow-up period. For safety, thrombocytosis (platelet count ≥400 × 109/L) was the most frequent adverse event (AE) observed in 44 children 97 times. Long-term treatment with avatrombopag in ITP children showed a rapid and sustained platelet response and good bleeding control without significant or new AEs.
引用
- Wang N, Wang Z, Liu J, et al. Long-term efficacy and safety of avatrombopag in Chinese children with primary immune thrombocytopenia: A real-world observational study. Br J Haematol. 2025. PMID: 39756414. doi:10.1111/bjh.19973
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。